Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Proteinuria affects most people with complement 3 glomerulopathy ...

Medically reviewed by Femi Aremu, PharmD Complement 3 glomerulopathy (C3G) is a rare type of kidney disease. There are two types: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).C3GN is ...

C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) are two rare kidney diseases. They’re both driven by activity of the complement system, which is a ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

In a phase three, double blind, placebo controlled trial, pegcetacoplan significantly reduced proteinuria compared with ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

C3G and IC-MPGN both cause protein deposits that reduce kidney function. Overactive proteins in the immune system lead to these different conditions. C3G and IC-MPGN are rare kidney conditions. They ...

Current treatment methods for C3 glomerulopathy (C3G) help support kidney function and suppress immune system activity. Emerging therapies interrupt the proteins responsible for disease activity. C3G ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...